These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 29195145

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G, Malvagia S, Materazzi S, Della Bona ML, Boenzi S, Martinelli D, Dionisi-Vici C.
    Anal Chem; 2012 Jan 17; 84(2):1184-8. PubMed ID: 22148291
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
    Sander J, Janzen N, Terhardt M, Sander S, Gökcay G, Demirkol M, Ozer I, Peter M, Das AM.
    Clin Chim Acta; 2011 Jan 14; 412(1-2):134-8. PubMed ID: 20883679
    [Abstract] [Full Text] [Related]

  • 6. Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.
    Rashed MS, Al-Ahaidib LY, Al-Dirbashi OY, Al Amoudi M, Al-Sayed MM, Rahbeeni Z, Al-Hassnan Z, Al-Dbaas A, Al-Owain M, Ni Luanaigh M.
    Anal Biochem; 2005 Apr 15; 339(2):310-7. PubMed ID: 15797572
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
    Herebian D, Spiekerkötter U, Lamshöft M, Thimm E, Laryea M, Mayatepek E.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May 15; 877(14-15):1453-9. PubMed ID: 19345648
    [Abstract] [Full Text] [Related]

  • 9. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G, Malvagia S, Pasquini E, Innocenti M, Fernandez MR, Donati MA, Zammarchi E.
    Rapid Commun Mass Spectrom; 2008 May 15; 22(6):812-8. PubMed ID: 18278819
    [Abstract] [Full Text] [Related]

  • 10. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.
    Prieto JA, Andrade F, Lage S, Aldámiz-Echevarría L.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr 01; 879(11-12):671-6. PubMed ID: 21377430
    [Abstract] [Full Text] [Related]

  • 11. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
    Kienstra NS, van Reemst HE, van Ginkel WG, Daly A, van Dam E, MacDonald A, Burgerhof JGM, de Blaauw P, McKiernan PJ, Heiner-Fokkema MR, van Spronsen FJ.
    J Inherit Metab Dis; 2018 Mar 01; 41(2):181-186. PubMed ID: 29170874
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.
    Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ.
    J Inherit Metab Dis; 2013 Jan 01; 36(1):15-20. PubMed ID: 22456946
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 - a case report.
    Zöggeler T, Ramoser G, Höller A, Jörg-Streller M, Janzen N, Ramoni A, Scholl-Bürgi S, Karall D.
    J Pediatr Endocrinol Metab; 2022 Feb 23; 35(2):259-265. PubMed ID: 34506697
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. LC-MS/MS study of the degradation processes of nitisinone and its by-products.
    Barchanska H, Rola R, Szczepankiewicz W, Mrachacz M.
    J Pharm Biomed Anal; 2019 Jul 15; 171():15-21. PubMed ID: 30959315
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.